Donepezil
Brand names: Aricept
Donepezil is an oral acetylcholinesterase inhibitor used for the symptomatic treatment of mild to moderate (and, at higher strength, severe) Alzheimer's disease.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It reversibly inhibits acetylcholinesterase, increasing synaptic acetylcholine to partially compensate for the cholinergic deficit characteristic of Alzheimer's disease.
Prescribing in practice
- Its cholinergic action can cause bradycardia and heart block, so use with caution in patients with conduction abnormalities, sick sinus syndrome or those on rate-limiting drugs, and review unexplained syncope.
- Cholinergic effects may also exacerbate asthma or COPD, peptic ulcer disease and bladder outflow obstruction, and lower the seizure threshold.
- Dose-related nausea, diarrhoea, insomnia and vivid dreams are common; taking it in the morning can reduce sleep disturbance.
Monitoring
Assess cognition, function and tolerability periodically and review cardiovascular status, including pulse, particularly in those with conduction risk factors.
Counselling the patient
- Nausea and loose stools are common initially and often settle.
- Report fainting, slow heartbeat or dizziness.
- It helps symptoms rather than curing the underlying condition.
Evidence & guidelines
NICE recommends acetylcholinesterase inhibitors including donepezil for managing mild to moderate Alzheimer's disease, supported by randomised trial evidence of symptomatic benefit.
Reference: NICE TA217; UK Dementia Prevention Commission; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
- BALL Score for Relapsed/Refractory CLL · Leukaemia
- Acute Stroke / TIA Assessment · NICE NG128; RCP Stroke Guidelines 2023
- Status Epilepticus (Adults) · NICE CG137; ESEM guidelines; RCP Neurology Guidelines
- Suspected Subarachnoid Haemorrhage · NICE NG228; RCEM 2023; AHA/ASA 2023
- Adult Head Injury · NICE NG232 (2023)
- Bell's Palsy / Facial Nerve Palsy · ENT UK 2017; AAN
- Vertigo Workup · ENT UK; NICE CKS